Apollon Inc. is a South Korean medtech startup founded in 2021 by Aram Hong, with a mission to develop non-invasive and convenient diagnostic tools without compromising clinical accuracy. The company is collaborating with the Massachusetts Institute of Technology (MIT) to develop and conduct clinical trials of continuous non-invasive glucose monitoring (CGM) technology using Raman spectroscopy.
Raman spectroscopy is a renowned technique that identifies substances based on their intrinsic vibrations detected when laser light scatters off them. Apollon leverages this non-destructive and non-invasive approach for material identification. The company aims to miniaturize the CGM device to make it wearable, building upon the preclinical findings published in Science Advances in 2020 that demonstrated direct measurement of glucose concentration through the skin with a mean absolute relative difference (MARD) of 6.6%.
Apollon's expertise lies in Raman diagnostics and spectrometer miniaturization. The company has published several research papers showcasing its capabilities, including using surface-enhanced Raman spectroscopy (SERS) for nucleic acid amplification and detection (ACS Nano, September 2023), label-free atherosclerosis diagnosis (Bioengineering & Translational Medicine, July 2023), and diagnosis of ischemic renal failure (Analytical Chemistry, December 2022).
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.